# US 2021/0330598 A1 · Amphotericin Loaded Pegylated Lipid Nanoparticles And Methods Of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330598 A1
- Document ID: US20210330598A1
- Status: Published application
- Kind: A1
- Application number: 17/265,644
- Filed: 2019-08-05
- Published: 2021-10-28
- Earliest claimed: 2018-08-03
- Assignees: The University of Mississippi
- Applicants: University of Mississippi
- Inventors: Soumyajit MAJUMDAR; Akash PATIL; Prit LAKHANI
- Web page: https://patentgrep.com/patent/US20210330598A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000 are described. Methods of administering nanolipid carrier molecules are also described. Also described is a method for treating fungal ocular infections by topical ocular administration of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000.

## Claims

### Claim 1

A nanostructured lipid carrier (NLC) comprising:
a combination of solid and liquid lipids; and
a PEG molecule, wherein the PEG has a molecular weight of between about 1000 and 5000, and
wherein the PEG molecule is partially or completely on the surface of the NLC.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The NLC of claim 1, wherein the PEG molecule has a molecular weight of between about 1000 and 3000.

### Claim 4 (depends on 1)

The NLC of claim 1, wherein the PEG molecule has a molecular weight of about 2000.

### Claim 5 (depends on 1)

The NLC of claim 1, wherein the PEG molecule is added as a PEG-lipid conjugate.

### Claim 6 (depends on 5)

The NLC of claim 5, wherein the PEG-lipid conjugate is mPEG-2000DSPE.

### Claim 7 (depends on 1)

The NLC of claim 1, wherein the liquid lipid is castor oil.

### Claim 8 (depends on 1)

The NLC of claim 1, further comprising a pharmaceutical, or combination of pharmaceuticals.

### Claim 9 (depends on 8)

The NLC of claim 8, wherein the pharmaceutical is amphotericin B.

### Claim 10 (depends on 9)

The NLC of claim 9, wherein the concentration of amphotericin B in a colloidal aqueous dispersion is from about 0.01% to about 0.5% w/v.

### Claim 11 (depends on 8)

The NLC of claim 8, further comprising a cryoprotectant.

### Claim 12 (depends on 9)

The NLC of claim 9, wherein the amphotericin B is loaded at about 1% to about 10% w/w of lipid content.

### Claim 13

(canceled)

### Claim 14 (depends on 9)

The NLC of claim 9, wherein the amphotericin B is loaded at about 4% to about 6% w/w of lipid content.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The NLC of claim 1, wherein the NLC has an average particle size of between about 200 nm and about 750 nm.

### Claim 17

(canceled)

### Claim 18 (depends on 8)

The NLC of claim 8, further comprising a preservative.

### Claim 19 (depends on 8)

The NLC of claim 8, further comprising polymeric ingredients to further stabilize and/or impart mucoadhesive characteristics to the NLC.

### Claim 20 (depends on 19)

The NLC of claim 19, wherein the polymeric ingredients include chitosan.

### Claim at position 21

21-47. (canceled)

### Claim 48 (depends on 1)

The NLC of claim 1, wherein the solid lipid is glyceryl distearate or glyceryl palmitostearate.

### Claim 49 (depends on 1)

The NLC of claim 1, wherein the NLC is provided as a powder or cake or in a colloidal aqueous dispersion.

### Claim 50 (depends on 49)

The NLC of claim 49, wherein the NLC is provided in an in situ gelling colloidal dispersion.

### Claim 51 (depends on 18)

The NLC of claim 18, wherein the preservative is Benzalkonium Chloride.
